BACKGROUND: 6-Bromo-7-[11C]methylpurine ([11C]BMP) is a radiotracer for positron emission tomography (PET) to measure multidrug resistance-associated protein 1 (MRP1) transport activity in different tissues. Previously reported radiosyntheses of [11C]BMP afforded a mixture of 7- and 9-[11C]methyl regioisomers. To prepare for clinical use, we here report an improved regioselective radiosynthesis of [11C]BMP, the results of a non-clinical toxicity study as well as human dosimetry estimates based on mouse PET data. RESULTS: [11C]BMP was synthesised by regioselective N7-methylation of 6-bromo-7H-purine (prepared under good manufacturing practice) with [11C]methyl triflate in presence of 2,2,6,6-tetramethylpiperidine magnesium chloride in a TRACERlab™ FX2 C synthesis module. [11C]BMP was obtained within a total synthesis time of approximately 43 min in a decay-corrected radiochemical yield of 20.5 ± 5.2%, based on starting [11C]methyl iodide, with a radiochemical purity > 99% and a molar activity at end of synthesis of 197 ± 130 GBq/μmol (n = 28). An extended single-dose toxicity study conducted in male and female Wistar rats under good laboratory practice after single intravenous (i.v.) administration of unlabelled BMP (2 mg/kg body weight) revealed no test item related adverse effects. Human dosimetry estimates, based on dynamic whole-body PET data in female C57BL/6J mice, suggested that an i.v. injected activity amount of 400 MBq of [11C]BMP will deliver an effective dose in the typical range of 11C-labelled radiotracers. CONCLUSIONS: [11C]BMP can be produced in sufficient amounts and acceptable quality for clinical use. Data from the non-clinical safety evaluation showed no adverse effects and suggested that the administration of [11C]BMP will be safe and well tolerated in humans.

Biomedical Research Center University Hospital Hradec Kralove Hradec Kralove Czech Republic

Department Computer Science University of Applied Sciences Technikum Wien Vienna Austria

Department of Biomedical Imaging and Image Guided Therapy Medical University of Vienna Vienna Austria

Department of Clinical Pharmacology Medical University of Vienna Vienna Austria

Department of Nuclear Medicine Medical University Innsbruck Innsbruck Austria

Department of Pharmacology Faculty of Medicine University of Latvia Rīga Latvia

Institute of Nutritional Medicine University of Lübeck and University Medical Center Schleswig Holstein Lübeck Germany

School of Neurobiology Biochemistry and Biophysics The Georg S Wise Faculty of Life Sciences Tel Aviv University Tel Aviv Israel

Section of Neuropathology Research Department of Pathology Clinics for Laboratory Medicine Oslo University Hospital Oslo Norway

Translational Neurodegeneration Research and Neuropathology Lab Department of Clinical Medicine Medical Faculty University of Oslo Oslo Norway

Zobrazit více v PubMed

Andersson M, Johansson L, Eckerman K, Mattsson S. IDAC-Dose 2.1, an internal dosimetry program for diagnostic nuclear medicine based on the ICRP adult reference voxel phantoms. EJNMMI Res. 2017;7:88. doi: 10.1186/s13550-017-0339-3. PubMed DOI PMC

Blau M. Letter: radiation dosimetry of 131-I-19-iodocholesterol: the pitfalls of using tissue concentration data. J Nucl Med. 1975;16:247–249. PubMed

Bolch WE, Eckerman KF, Sgouros G, Thomas SR. MIRD pamphlet No. 21: a generalized schema for radiopharmaceutical dosimetry–standardization of nomenclature. J Nucl Med. 2009;50:477–84. doi: 10.2967/jnumed.108.056036. PubMed DOI

Chen S, Graceffa RF, Boezio AA. Direct, regioselective N-alkylation of 1,3-azoles. Org Lett. 2016;18:16–19. doi: 10.1021/acs.orglett.5b02994. PubMed DOI

Cole SP. Multidrug resistance protein 1 (MRP1, ABCC1), a "multitasking" ATP-binding cassette (ABC) transporter. J Biol Chem. 2014;289:30880–30888. doi: 10.1074/jbc.R114.609248. PubMed DOI PMC

EMA. European Medicines Agency. ICH guideline M3(R2) on non-clinical safety studies for the conduct of human clinical trials and marketing authorisation for pharmaceuticals. 2009; EMA/CPMP/ICH/286/1995.

EMA. European Medicines Agency. Committee for Medicinal Products for Human Use. Guideline on the non-clinical requirements for radiopharmaceuticals. 2018; EMA/CHMP/SWP/686140/2018.

EMA. European Medicines Agency. Committee for Medicinal Products for Human Use. Guideline on the requirements to the chemical and pharmaceutical quality documentation concerning investigational medicinal products in clinical trials. 2022; EMA/CHMP/QWP/545525/2017 Rev. 2.

ICRP Radiological Protection in biomedical research. ICRP publication 62. Ann ICRP. 1992;22:1–18. PubMed

ICRP The 2007 recommendations of the international commission on radiological protection. ICRP publication 103. Ann ICRP. 2007;2007(37):1–332. PubMed

Jewett DM. A simple synthesis of [11C]methyl triflate. Appl Radiat Isot. 1992;43:1383–1385. doi: 10.1016/0883-2889(92)90012-4. PubMed DOI

Krohn M, Lange C, Hofrichter J, Scheffler K, Stenzel J, Steffen J, et al. Cerebral amyloid-beta proteostasis is regulated by the membrane transport protein ABCC1 in mice. J Clin Invest. 2011;121:3924–3931. doi: 10.1172/JCI57867. PubMed DOI PMC

Krohn M, Zoufal V, Mairinger S, Wanek T, Paarmann K, Bruning T, et al. Generation and characterization of an Abcc1 humanized mouse model (hABCC1flx/flx) with knockout capability. Mol Pharmacol. 2019;96:138–147. doi: 10.1124/mol.119.115824. PubMed DOI

Larsen P, Ulin J, Dahlstrøm K, Jensen M. Synthesis of [11C]iodomethane by iodination of [11C]methane. Appl Radiat Isot. 1997;48:153–157. doi: 10.1016/S0969-8043(96)00177-7. DOI

Loevinger R, Budinger TF, Watson EE, Society of Nuclear Medicine (1953- ) Medical , MIRD primer for absorbed dose calculations. Rev. New York, NY: Society of Nuclear Medicine; 1991.

Mairinger S, Sake JA, Hernández Lozano I, Filip T, Sauberer M, Stanek J, et al. Assessing the activity of multidrug resistance-associated protein 1 at the lung epithelial barrier. J Nucl Med. 2020;61:1650–1657. doi: 10.2967/jnumed.120.244038. PubMed DOI

Mairinger S, Hernández-Lozano I, Zachhuber L, Filip T, Lobsch M, Zeitlinger M, et al. Effect of budesonide on pulmonary activity of multidrug resistance-associated protein 1 assessed with PET imaging in rats. Eur J Pharm Sci. 2023;184:106414. doi: 10.1016/j.ejps.2023.106414. PubMed DOI

Menzel H, Clement C, DeLuca PM. ICRP Publication 110. Realistic reference phantoms: an ICRP/ICRU joint effort. A report of adult reference computational phantoms. 2009. PubMed

Okamura T, Kikuchi T, Fukushi K, Arano Y, Irie T. A novel noninvasive method for assessing glutathione-conjugate efflux systems in the brain. Bioorg Med Chem. 2007;15:3127–3133. doi: 10.1016/j.bmc.2007.02.045. PubMed DOI

Okamura T, Kikuchi T, Fukushi K, Irie T. Reactivity of 6-halopurine analogs with glutathione as a radiotracer for assessing function of multidrug resistance-associated protein 1. J Med Chem. 2009;52:7284–7288. doi: 10.1021/jm901332c. PubMed DOI

Okamura T, Kikuchi T, Okada M, Toramatsu C, Fukushi K, Takei M, et al. Noninvasive and quantitative assessment of the function of multidrug resistance-associated protein 1 in the living brain. J Cereb Blood Flow Metab. 2009;29:504–511. doi: 10.1038/jcbfm.2008.135. PubMed DOI

Okamura T, Kikuchi T, Okada M, Wakizaka H, Zhang MR. Imaging of activity of multidrug resistance-associated protein 1 in the lungs. Am J Respir Cell Mol Biol. 2013;49:335–340. doi: 10.1165/rcmb.2012-0275MA. PubMed DOI

Okamura T, Kikuchi T, Ogawa M, Zhang MR. Improved synthesis of 6-bromo-7-[11C]methylpurine for clinical use. EJNMMI Radiopharm Chem. 2024;9:10. doi: 10.1186/s41181-024-00240-8. PubMed DOI PMC

Pahnke J, Langer O, Krohn M. Alzheimer's and ABC transporters–new opportunities for diagnostics and treatment. Neurobiol Dis. 2014;72:54–60. doi: 10.1016/j.nbd.2014.04.001. PubMed DOI PMC

Peñuelas I, Vugts DJ, Decristoforo C, Elsinga PH. The new Regulation on clinical trials in relation to radiopharmaceuticals: when and how will it be implemented? EJNMMI Radiopharm Chem. 2019;4:2. doi: 10.1186/s41181-019-0055-6. PubMed DOI PMC

Sartorelli AC, Booth BA, Robins RK. Comparison of some biological and biochemical properties of 6-bromopurine and 6-iodopurine. Biochem Pharmacol. 1962;11:1017–1024. doi: 10.1016/0006-2952(62)90159-4. PubMed DOI

Stabin MG. Fundamentals of nuclear medicine dosimetry. New York: Springer; 2008.

Todde S, Windhorst AD, Behe M, Bormans G, Decristoforo C, Faivre-Chauvet A, et al. EANM guideline for the preparation of an investigational medicinal product dossier (IMPD) Eur J Nucl Med Mol Imaging. 2014;41:2175–2185. doi: 10.1007/s00259-014-2866-8. PubMed DOI

van der Deen M, Marks H, Willemse BW, Postma DS, Muller M, Smit EF, et al. Diminished expression of multidrug resistance-associated protein 1 (MRP1) in bronchial epithelium of COPD patients. Virchows Arch. 2006;449:682–688. doi: 10.1007/s00428-006-0240-3. PubMed DOI

Zanotti-Fregonara P, Lammertsma AA, Innis RB. 11C dosimetry scans should be abandoned. J Nucl Med. 2021;62:158–159. doi: 10.2967/jnumed.120.257402. PubMed DOI PMC

Zoufal V, Mairinger S, Krohn M, Wanek T, Filip T, Sauberer M, et al. Influence of multidrug resistance-associated proteins on the excretion of the ABCC1 imaging probe 6-bromo-7-[11C]methylpurine in mice. Mol Imaging Biol. 2019;21:306–316. doi: 10.1007/s11307-018-1230-y. PubMed DOI PMC

Zoufal V, Mairinger S, Krohn M, Wanek T, Filip T, Sauberer M, et al. Measurement of cerebral ABCC1 transport activity in wild-type and APP/PS1-21 mice with positron emission tomography. J Cereb Blood Flow Metab. 2020;40:954–965. doi: 10.1177/0271678X19854541. PubMed DOI PMC